<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04705142</url>
  </required_header>
  <id_info>
    <org_study_id>Ref No. IRB/2019/527/SIMS</org_study_id>
    <nct_id>NCT04705142</nct_id>
  </id_info>
  <brief_title>Beneficial Effect of Intravenous Magnesium Sulphate in Term Neonates With Hypoxic Ischemic Encephalopathy(HIE)</brief_title>
  <official_title>Beneficial Effect of Intravenous Magnesium Sulphate in Term Neonates With Hypoxic Ischemic Encephalopathy(HIE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Services Institute of Medical Sciences, Pakistan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Services Institute of Medical Sciences, Pakistan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neonatal mortality rate is the highest in Pakistan. And Birth Asphyxia is one of the main&#xD;
      reversible causes. Outcomes related to birth asphyxia can be improved, if intervention done&#xD;
      in time with proper measures. MgSO4 is cheaper and easily available drug.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Some studies showed positive results if given within 6 hours of birth asphyxia, whereas some&#xD;
      are not supportive. But still less know about this drug, especially in low income countries.&#xD;
      Objective of this study is to see beneficial effects of MgSO4 in neonates presenting with&#xD;
      birth asphyxia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Actual">December 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Case control study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Blinded Study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Immediate complications of disease</measure>
    <time_frame>2 weeks</time_frame>
    <description>Reduction in Immediate complications of disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction in mortality</measure>
    <time_frame>2 weeks</time_frame>
    <description>Reduction in mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction in hospital stay</measure>
    <time_frame>2 weeks</time_frame>
    <description>Reduction in hospital stay</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>HIE</condition>
  <arm_group>
    <arm_group_label>MgSO4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MgSO4&#xD;
1st dose within 6 hours of life @250mg/kg,2nd after 24 hours of life @250mg/kg, 3rd after 48 hours of life @250mg/kg.&#xD;
Monitoring and Protective measures:&#xD;
Before and during administration of MgSO4, B.P, Capillary refill time, Heart rate and respiratory rate will be assessed closely i-e on 10 minutes interval, infusion of MgSO4 will be give over 30 minutes and baby will be monitored every 15 minutes interval after completion of infusion as well for 1 hour.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MgSo4</intervention_name>
    <description>Before and during administration of MgSO4, B.P, Capillary refill time, Heart rate and respiratory rate will be assessed closely i-e on 10 minutes interval, infusion of MgSO4 will be give over 30 minutes and baby will be monitored every 15 minutes interval after completion of infusion as well for 1 hour.</description>
    <arm_group_label>MgSO4</arm_group_label>
    <other_name>Conventional Treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  After informed consent, any child who is term, inborn or out born fulfilling the&#xD;
             definition of hypoxic ischemic encephalopathy according to history, apgar or scoring&#xD;
             system and reaching within 6 hours of delivery in nursery department of pediatric&#xD;
             medicine unit-II, Services Hospital, Lahore&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Preterm Syndromic/dysmorphic child Term child with HIE and arriving after 6 hours of&#xD;
             life. Term child with unrelated co morbidities eg congenital heart defects, Renal&#xD;
             failure etc&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Uzair Ahmed, MBBS, FCPS</last_name>
    <role>Study Director</role>
    <affiliation>Associate Prof, Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Services Institute of Medical Sciences, Lahore</name>
      <address>
        <city>Lahore</city>
        <state>Punjab</state>
        <zip>54000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3087983/</url>
    <description>Reference Study</description>
  </link>
  <reference>
    <citation>Gathwala G, Khera A, Singh J, Balhara B. Magnesium for neuroprotection in birth asphyxia. J Pediatr Neurosci. 2010 Jul;5(2):102-4. doi: 10.4103/1817-1745.76094.</citation>
    <PMID>21559152</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 21, 2020</study_first_submitted>
  <study_first_submitted_qc>January 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2021</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIE, MgSO4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Hypoxia-Ischemia, Brain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>After family consent, decision will be reviewed</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

